Exposure of Tenon's capsule fibroblasts of pterygium to cyclosporin 0.05%;Exposição de fibroblastos da cápsula de Tenon de pterígios à ciclosporina 0,05%

Arquivos Brasileiros de Oftalmologia

Volumn 69, Issue 6, 2006, Pages 831-835

  Hercules, Laura Almeida ^a   Hata Viveiros, Magda Massae ^a   Schellini, Silvana Artioli ^a   Candeias, João ^a   Padovani, Carlos Roberto ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cell culture techniques; Cyclosporins; Fibroblasts; Immunosuppressive agents; Pterygium

Indexed keywords

EID: 33846844843     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492006000600010     Document Type: Article

References (18)

1. Duke-Elder WS. Textbook of ophthalmology. St Louis: Mosby. 1954. v.7. p.570-86.
2. Kwok LS, Coroneo MT. A model for pterygium formation. Cornea. 1994; 13(3):219-24.
3. Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol. 2000;84(2):212-6.
4. Pyrzynska B, Serrano M, Martinez-A C, Kaminska B. Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A. J Biol Chem. 2002; 277(16):14102-8.
5. Hernandez GL, Volpert OV, Iniguez MA, Lourenzo E, Martinez-Martinez S, Grau R, et al. Selective inhibition of vascular endothelial growth factor - mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193(5):607-20.
6. Liu L, Yang D. Immunological studies on the pathogenesis of pterygium. Chin Med Sci J. 1993;8(2):84-8.
7. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984;98(2):225-8.
8. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118(11):1489-96.
9. Perry HD, Donnenfeld ED. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother. 2004;5(10):2099-107.
10. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89(3):298-303.
11. Bhargava A, Jackson WB, El-Defrawy SR. Ocular allergic disease. Drugs Today (Barc). 1998;34(11):957-71.
12. Leonardi A, DeFranchis G, Fregona IA, Violato D, Plebani M, Secchi AG. Effects of cyclosporin A on human conjunctival fibroblasts. Arch Ophthalmol. 2001;119(10):1512-7.
13. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24(1):80-5.
14. Theng J, Zhou L, Tan D, La KW. Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther. 2002;18(1):83-8.
15. Norman GR, Streiner DL. Biostatistics: the bare essentials. St. Louis: Mosby. 1994. 240p.
16. Viveiros MMH, Schellini SA, Rainho C, Rogatto SR, Padovani CR. Análise do cultivo de fibroblastos da cápsula de Tenon de pterígios primários e recidivados [abstract]. Arq Bras Oftalmol. 2004;67(4 Supl):37. [Resumos dos Temas Livres do XVI Congresso Brasileiro de Prevenção da Cegueira e Reabilitação Visual].
17. Wu H, Chen G. [Cyclosporine A and thiotepa in prevention of postoperative recurrence of pterygium]. Yan Ke Xue Bao. 1999;15(2):91-2. Chinese.
18. Hasegawa DS, Hoyama E, Dalamas JC, Hasegawa N, Yagui N. Uso de ciclosporina 0,05% colírio no pós-operatório do pterígio [abstract]. In: XXX International Congress of Ophthalmology; 2006 Feb 19-24. Abstract Book. São Paulo. 2006. p.64.